CompanyGraph
What stands out
- Dividend several times the last twelve months' earnings
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionP/E ratio is 372×, higher than 95% of its Biotechnology peers (median 32.17×)
- FinancialsAltman Z-Score 3.09: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Dividend several times the last twelve months' earnings
Dividends view
Yield
1.34%Above 5Y avg (1.03%)
Annual Rate
CNY 0.25Paid annual
Payout Ratio
500.0%High
Payback Period
75.6 yr
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.18BCNY474.61M · vs all stocks (USD)
Trailing P/E
372.00xvs Biotechnology peers
Revenue (TTM)
1.23BCNY183.77M · vs all stocks (USD)
Profit Margin
0.81%vs Biotechnology peers
Beta
0.4940xvs all stocks
52-Week Change
-34.09%vs all stocks
Market Capitalization
3.18BCNY474.61M · vs all stocks (USD)
Enterprise Value
3.01BCNY449.01M · vs all stocks (USD)
Trailing P/E
372.00xvs Biotechnology peers
Forward P/E
12.16xvs Biotechnology peers
Price to Sales (TTM)
2.58xvs Biotechnology peers
Price to Book (MRQ)
2.22xvs Biotechnology peers
Enterprise to Revenue
2.44xvs Biotechnology peers
Enterprise to EBITDA
41.90xvs Biotechnology peers
Gross Margin
81.84%vs Biotechnology peers
Profit Margin
0.81%vs Biotechnology peers
Operating Margin
11.26%vs Biotechnology peers
Return on Assets (TTM)
0.40%vs Biotechnology peers
Return on Equity (TTM)
0.41%vs Biotechnology peers
Revenue (TTM)
1.23BCNY183.77M · vs all stocks (USD)
Revenue per Share (TTM)
7.05CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-19.40%vs Biotechnology peers
Gross Profit (TTM)
861.64MCNY128.62M · vs all stocks (USD)
EBITDA (TTM)
162.66MCNY24.28M · vs all stocks (USD)
Net Income (TTM)
9.96MCNY1.49M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-5.10%vs Biotechnology peers
Operating Cash Flow (TTM)
105.19MCNY15.70M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-91.66MCNY-13.68M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2500CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
1.34%vs all stocks
5-Year Average Dividend Yield
1.03%vs all stocks
Payout Ratio
500.00%vs Biotechnology peers
Minority Interest (Equity)
32.67MCNYFY2025 · Dec 31, 2025Revenue
1.32BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
235.68MCNYFY2025 · Dec 31, 2025Gross Profit
1.09BCNYFY2025 · Dec 31, 2025Operating Income
192.78MCNY28.78M · vs all stocks (USD)
Pre-tax Income
53.73MCNYFY2025 · Dec 31, 2025Income Tax Expense
13.47MCNYFY2025 · Dec 31, 2025Net Income
40.26MCNYFY2025 · Dec 31, 2025EBIT
56.60MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
247.52MCNYFY2025 · Dec 31, 2025Research & Development
140.90MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
654.64MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.60MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.87MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1800CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
169.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
169.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
40.26MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-9.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-53.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
-187.04MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
711.45MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
40.26MCNYFY2025 · Dec 31, 2025Other Non-cash Items
6.97MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-92.33MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.61MCNYFY2025 · Dec 31, 2025Capital Expenditures
-133.33MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.18BCNYFY2025 · Dec 31, 2025Sale of Investments
997.51MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-315.10MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
418.71MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-86.20MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-56.04MCNYFY2025 · Dec 31, 2025Other Financing Charges
-165.89MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
110.58MCNYFY2025 · Dec 31, 2025Shares Outstanding
170.94MSharesUpdated Sep 22, 2026Float Shares
150.08MSharesUpdated Sep 22, 2026% Held by Insiders
30.50%vs all stocks
% Held by Institutions
1.43%vs all stocks
Total Cash (MRQ)
1.22BCNY181.77M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.99CNYUpdated Sep 22, 2026Total Debt (MRQ)
409.16MCNY61.07M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2350xvs Biotechnology peers
Current Ratio (MRQ)
3.70xvs Biotechnology peers
Book Value per Share (MRQ)
8.39CNYUpdated Sep 22, 2026Total Assets
2.79BCNY416.93M · vs all stocks (USD)
Total Current Assets
1.95BCNYFY2025 · Dec 31, 2025Total Liabilities
1.05BCNYFY2025 · Dec 31, 2025Total Non-current Assets
838.32MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
350.95MCNYFY2025 · Dec 31, 2025Total Current Liabilities
702.33MCNYFY2025 · Dec 31, 2025Cash
713.32MCNYFY2025 · Dec 31, 2025Cash Equivalents
120.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
833.97MCNYFY2025 · Dec 31, 2025Other Short-term Investments
287.50MCNYFY2025 · Dec 31, 2025Accounts Receivable
441.37MCNYFY2025 · Dec 31, 2025Inventory
136.01MCNYFY2025 · Dec 31, 2025Accounts Payable
336.49MCNYFY2025 · Dec 31, 2025Short-term Debt
240.90MCNYFY2025 · Dec 31, 2025Other Current Liabilities
145.62KCNYFY2025 · Dec 31, 2025Long-term Debt
263.44MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
24.87MCNYFY2025 · Dec 31, 2025Common Stock (Book)
170.94MCNYFY2025 · Dec 31, 2025Retained Earnings
403.40MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.74BCNY259.71M · vs all stocks (USD)
Treasury Stock
45.06MCNYFY2025 · Dec 31, 202552-Week Low
14.61CNYUpdated Sep 22, 202652-Week High
29.81CNYUpdated Sep 22, 202652-Week Change
-34.09%vs all stocks
Beta
0.4940xvs all stocks
50-Day MA
17.25CNYUpdated Sep 22, 2026200-Day MA
19.90CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.42MSharesUpdated Sep 22, 2026Avg 30-Day Volume
3.22MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.0500CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 372×, higher than 95% of its Biotechnology peers (median 32.17×)Significant
P/E ratio: 372Industry median: 32.17Industry P95: 323.745Peers compared: 260
Structural Tensions
Dividend several times the last twelve months' earningsSignificant
Payout Ratio: 5.00Dividend per Share: 0.25Earnings per Share: 0.05
High gross margins eroded by operating costsNotable
Gross Margin: 0.82Profit Margin: 0.01
Financial Health
Altman Z-Score 3.09: safe zoneNotable
Altman Z-Score: 3.09
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Blau Farmacêutica S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hyundai Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yungshin Global Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jenscare Scientific Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Beijing Leadman Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Concord Biotech Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Tata Motors Ltd.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Zhengyuan Zhihui Group Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated